Zafirlukast: The first leukotriene-receptor antagonist approved for the treatment of asthma

Annals of Pharmacotherapy

Volumn 31, Issue 9, 1997, Pages 1012-1021

  Kelloway, Judy Shepard ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PARK NICOLLET CLINIC   (United States)

^c Zafirlukast   (United States)

Author keywords

Asthma; Leukotriene receptor antagonist; Zafirlukast

Indexed keywords

LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; THROMBOCYTE ACTIVATING FACTOR; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ECCHYMOSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALAISE; METABOLIC ACIDOSIS; MULTICENTER STUDY; MYALGIA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; WHEEZING;

EID: 0030866313     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100912     Document Type: Review

References (43)

1. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-6.
2. Krell RD, Aharony D, Buckner CK, Keith RA, Kusner EJ, Snyder DW, et al. The preclinical pharmacology of ICI 204,219, a peptide leukotriene antagonist. Am Rev Respir Dis 1990;141:978-87.
3. Buckner CK, Fedyna JS, Robertson JL, Will JA, England DM, Krell RD, et al. An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways. J Pharmacol Exp Ther 1990;252:77-85.
4. Krell RD, Dehaas CJ, Lengel DJ, Kusner EJ, Williams JC, Buckner CK. Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICI 204,219 (Accolate). Ann N Y Acad Sci 1993;744:289-98.
5. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990; 141:988-92.
6. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI-204,219. Clin Pharmacol Ther 1993;54:430-6.
7. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993;147:215-7.
8. Product information. Accolate (zafirlukast). Wilmington, DE: Zeneca Pharmaceuticals, revised September 1996.
9. 4 receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
10. Dahlén B, Zetterström O, Björck T, Dahlén S-E. The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994;7: 324-31.
11. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene-receptor antagonist ICI 204,219 on allergen induced bronchoconstriction and airways hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
12. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89:1040-5.
13. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:1413-8.
14. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase response of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993;147: 1431-5.
15. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994;105:483-8.
16. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma (abstract). J Allergy Clin Immunol 1994;93(1 part 2):295.
17. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150: 618-23.
18. Lockey RF, Lavins BJ, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) in patients with mild-to-moderate asthma (abstract). J Allergy Clin Immunol 1995;95:350.
19. Rosenthal R, Lavins BJ, Hanby LA. Effect of treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma (abstract). J Allergy Clin Immunol 1996;97:250.
20. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 ('Accolate') or cromolyn sodium ('Intal') in patients with mild to moderate asthma (abstract). J Allergy Clin Immunol 1995;95:388.
21. Spector SL. Update on exercise-induced asthma. Ann Allergy 1993;71: 571-7.
22. 4 concentrations increase after aspirin challege in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
23. Christie PE, Smith CM, Lee TH. The potent and selective suphidopeptide leukotriene antagonist SKF 104353 inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
24. Dahlén B, Margolskee DJ, Zetterström O, Dahlén SF. Effect of leukotriene antagonist MK 0679 on baseline pulmonary function in aspirin-sensitive asthmatics. Thorax 1993;48:1205-10.
25. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9.
26. Sibbald B, Strachan DP. Epidemiology of rhinitis. In: Busse WW, Holgate ST, eds. Asthma and rhinitis. Cambridge, MA: Blackwell Scientific Publications, 1995:36.
27. Data on file. Zeneca Pharmaceuticals, Wilmington, DE.
28. Spector SL, Nicklas RA. Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1996;5(part 2):707-870.
29. National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, publication no. 91-3042; 1991.
30. Global Initiative for Asthma. Global strategy for asthma management and prevention, NHLBI/NIH workshop report. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, publication no. 95-3659; 1995.
31. Kaliner M. Goals of asthma therapy. Ann Allergy Asthma Immunol 1995;75:169-72.
32. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208.
33. Kamada AK, Szefler SJ, Martin RJ, Boshev HA, Chinchilli VM, Drazen JM. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996;153:1739-48.
34. Mellins RB, Evans D, Zimmerman B, Clark NM. Patient compliance. Are we wasting our time and don't know it? Am Rev Respir Dis 1992; 146:1376-7.
35. Wright EC. Noncompliance - or how many units has Matilda? Lancet 1993;342:909-13.
36. Morris LS, Schulz RM. Patient compliance: an overview. J Clin Pharm Ther 1992;17:283-95.
37. Compton G. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982;119(suppl):101-4.
38. Pedersen S, Frost L, Arafred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986;41:118-24.
39. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-52.
40. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996;334:1380-8.
41. Israel E, Rubin P, Kemp J, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
42. Israel E, Conn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996;275:931-6.
43. Package insert. Zyflo filmtab (zileuton). Abbott Park, IL: Abbott Laboratories, December 1996.